Announced Mon, 17 Aug · 16:28 IST
Q1 FY27: Revenue up 42% at INR 535 cr, EBITDA margin 25.4%
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDFExplain this filing
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.4%1-day move
₹864.00
prior close
₹861.95
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.2+3.0+2.1+1.8-3.4-3.6-5.4———————
Up moveDown movePending
AI summary
Aarti Pharmalabs Q1 FY27 standalone revenue rose 42% YoY to INR 535 cr, with EBITDA up 40% to INR 133 cr and PAT up 49% to INR 71 cr. EBITDA margin was 25.4%. Xanthine derivatives led at 57% of sales, API and Intermediates 30%, CDMO 7%. Management guided full year EBITDA margin at 22-25% and Xanthine revenue at INR 900-1,100 cr. CDMO growth guided at 40-50% with target of INR 1,000 cr by FY29-30. INR 149 cr capex announced for new Atali Block 2.
Likely market impact
Strong quarter driven by elevated Xanthine prices; margins to normalize but stay healthy. CDMO ramp-up remains key growth driver.